Risk of Virological Failure After Switch to a Tenofovir-Sparing Dual Therapy in Virologically Suppressed People With HIV and Past HBV Infection. | ClinicLens

We compared the effectiveness of tenofovir (TFV)-based triple regimens (TT) to TFV-sparing dual therapies (DT) in virologically suppressed, HBsAg-/HBcAb+ people living with HIV (PLWH). We emulated a target trial including adults PLWH from five University Hospitals, with HBsAg-/HB

Medical Literature · Updated 2026-08-02

← Back to articles

This standalone article is served from the ClinicLens content archive.

If the embedded page does not load in your browser, open it directly.